

The Catch 22 of Becoming a Useful Resource; Lessons Learn(ing)ed by the LCCC Consortium Investigator-Initiated Trials Office

Kerrie Briggs Bouker, PhD¹; Shaunice Shreeves, MS¹; Joshua Zenreich², Meghan N Mavredes, MPH¹

¹Georgetown Lombardi Comprehensive Cancer Center, ²John Theurer Cancer Center

Background

Since mid-2022, the Lombardi Comprehensive Cancer Center (LCCC) Consortium Investigator-Initiated Trials (IIT) Office has provided wraparound support for all interventional/treatment IITs cross-consortium. The IIT Office supports LCCC in meeting NCI-designated metrics: time to activation (TTA), portfolio composition, and accruals. In 2023, the IIT Office successfully encouraged investigators to submit their IIT concepts to the IIT Steering Committee at an earlier stage (29 percent submitted at LOI stage in 2022 vs 69 percent in 2023) to ensure early IIT Office intervention in protocol development and study start-up. This also resulted in a reduction in TTA of therapeutic IITs by 41 percent between 2021 and 2023. In light of its successes in 2023, the IIT Office was challenged to continue its progress, a request that was complicated by LCCC leadership tasking Lombardi investigators to significantly increase enrollment to therapeutic trials.

Goals

Continued support of LCCC's goal to decrease TTA, balance portfolio composition, and increase accruals to LCCC IITs, by providing support for all interventional/treatment trials from concept through closeout, while optimizing workflow to navigate within changing LCCC enrollment goals.

Solutions and Methods

- 1) Enhance already existing IIT workflow by:
 - a. Creating new, and better utilizing existing, trackers to maximize IIT Office staff bandwidth (e.g., regulatory start-up/maintenance, DSMC safety review, study development, patient enrollment)
 - b. Intensifying protocol development assistance to ensure studies enter the regulatory process with accurate protocols, helping to decrease TTA and regulatory maintenance work
 - c. Increasing communication within Lombardi Clinical Trials Office, cross-consortium, and with ancillary departments to revamp existing processes for IIT support
- 2) Optimize regulatory sequence to decrease TTA by doing a head-to-head comparison
- 3) Bolster IIT Data support by:
 - a. LCCC's investment in a dedicated IIT data coordinator (DC)
 - b. Delegating all DCs to all IITs, giving data team increased agility
 - c. Creating CRF questionnaire, given to investigators at study start-up to streamline the number of CRFs for all new IITs and reduce overall IIT data burden




Figure 1: Average time-to-activation of LCCC interventional/ treatment IITs by year




Figure 2: Institutional interventional treatment accruals per year




Figure 3: IIT data optimization workflow

Outcomes

- ↑ number of activated interventional/treatment trials (8 in 2024 vs 4 in 2022 and 5 in 2023)
- Supported dramatic 62% ↑ increase in interventional/treatment IITs accruals between 2023 and 2024, with 20% of these enrollments coming from IITs activated in 2024 (Figure 1)
- ↓ Decreased TTA of interventional/treatment trials by roughly 50% from 2023 to 2024, with an overall 70% decrease in TTA since IIT Office opening (Figure 2)

Lessons Learned and Future Directions

With increased utilization of the IIT Office came increasing challenges, taxing existing IIT resources. This year required strategic thinking and further institutional support IIT regulatory specialist, IIT coordinators, and the CTO data team all saw increased workloads.

The successes of 2023 and the increasing accruals goals forced the IIT Office to optimize operations in 2024 across IIT data (Figure 3), regulatory, and study coordination. Better trackers, increased communication, additional protocol development assistance, and improved data team agility/support were instrumental to continued success.

Next year will require the IIT Office to further harness the power of the consortium by sharing responsibilities (e.g., study monitoring, patient enrollment) to maximize IIT support.

Contact

Kerrie Briggs Bouker, PhD
LCCC Consortium IIT Office
Lombardi Clinical Trials Office
Georgetown University
3900 Reservoir Rd., NW
Washington, DC 20007
briggsk@georgetown.edu